National Bank of Canada
ORMP icon

National Bank of Canada’s Oramed Pharmaceuticals ORMP Stock Holding History

National Bank of Canada’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,000
Closed -$4.38K – 3119
2025
Q2 		$4.38K Hold
2,000
– – ﹤0.01% 2513
2025
Q1 		$4.24K Sell
2,000
-500
-20% -$1.15K ﹤0.01% 2404
2024
Q4 		$6.05K Buy
+2,500
New +$5.94K ﹤0.01% 2418

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.37B AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

National Bank of Canada's ORMP Position: Q3 2025 in Review

National Bank of Canada sold out of Oramed Pharmaceuticals (ORMP) in Q3 2025, closing a stake of 2,000 shares — an estimated $4.38K sold.

National Bank of Canada first reported a position in ORMP in Q4 2024 and held it in 3 quarters. The position peaked at $6.05K in Q4 2024. 47 funds tracked by Wall St. Rank hold ORMP as of Q3 2025.

  • National Bank of Canada reported no remaining Oramed Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • National Bank of Canada sold 2,000 Oramed Pharmaceuticals shares in Q3 2025, an estimated $4.38K.
  • National Bank of Canada first reported a position in Oramed Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • National Bank of Canada's Oramed Pharmaceuticals position peaked at $6.05K in Q4 2024.
  • 47 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2025.

Based on National Bank of Canada's 13F filing for Q3 2025, filed 14 Nov 2025.